Ribosome display and affinity maturation: From antibodies to single V-domains and steps towards cancer therapeutics

Journal of Immunological Methods

Volumn 248, Issue 1-2, 2001, Pages 31-45

  Irving, Robert A ^a   Coia, Gregory ^a   Roberts, Anthony ^a   Nuttall, Stewart D ^a   Hudson, Peter J ^a  

^a CSIRO   (Australia)

Author keywords

Affinity maturation; Antibody engineering; Phage display; Ribosome display; Single chain Fvs; V domains

Indexed keywords

ANTIBODY; GLYCOPHORIN A; IMMUNOGLOBULIN; MESSENGER RNA; OLIGONUCLEOTIDE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG;

BACTERIOPHAGE; BINDING AFFINITY; CANCER THERAPY; COMPLEMENTARITY DETERMINING REGION; DNA SEQUENCE; GENE CONSTRUCT; GENETIC TRANSCRIPTION; MOLECULAR EVOLUTION; PHAGE DISPLAY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN ISOLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REVIEW; RIBOSOME;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY AFFINITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MOLECULAR SEQUENCE DATA; NEOPLASMS; PEPTIDE LIBRARY; PROTEIN BIOSYNTHESIS; PROTEIN FOLDING; RIBOSOMES; RNA REPLICASE; TRANSCRIPTION, GENETIC;

EID: 0035251462     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(00)00341-0     Document Type: Article

References (79)

1. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies
2. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library
3. Antibody humanisation using monovalent phage display
4. Placement of protein and RNA structures into a 5A resolution map of the 50S ribosomal subunit
5. The proportion of revertant and mutant phage in a growing population, as a function of mutation and growth rate
6. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent
7. Translation rates of individual codons are not correlated with tRNA abundances or with the frequencies of utilization in Escherichia coli
8. Display technologies expand their horizons
9. Engineering antibodies for imaging and therapy
10. Use of mutator cells as a means for increasing production levels of a recombinant antibody directed against Hepatitis B
11. Antibody VH domains as small recognition units
12. Single antibody domains as small recognition units: Design and in vitro antigen selection of camelized, human VH domains with improved protein stability
13. Affinity improvement of single antibody VH domains: Residues in all three hypervariable regions affect antigen binding
14. A large non-immunized human fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies
15. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme
16. Antibody arrays for high-throughput screening of antibody-antigen interactions and differentially expressed proteins
17. Effects of substitutions in an antibody binding surface on antigen affinity
18. Rates of spontaneous mutation among RNA viruses
19. The distribution of rates of spontaneous mutation over viruses, prokaryotes, and eukaryotes
20. Mutation rates among RNA viruses
21. Cotranslational protein folding
22. Identification of framework residues in a secreted recombinant antibody fragment that control production level and localisation in E. coli
23. Beyond binding: Using phage display to select for structure, folding and enzymatic activity in proteins
24. High-affinity peptide ligands to prostate-specific antigen identified by polysome selection
25. Immunotoxins for the treatment of B-cell lymphomas
26. The disulphide bonds in antibody variable domains: Effects on stability, folding in vitro, and functional expression in Escherichia coli
27. Asphyxial brain injury - The role of the IGF system
28. Naturally occurring antibodies devoid of light chains
29. In vitro selection and evolution of functional proteins by using ribosome display
30. Ribosome display efficiently selects and evolves high affinity antibodies in vitro from immune libraries
31. Comparison of Escherichia coli and rabbit reticulocyte ribosome display systems
32. Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites
33. Selection of a human anti-progesterone fragment from a transgenic mouse library by ARM ribosome display
34. Antibody phage display technology and its applications
35. Recombinant antibody constructs in cancer therapy
36. Development and application of cytotoxic T lymphocyte-associated antigen 4 asa protein scaffold for the generation of novel binding ligands
37. Affinity maturation of recombinant antibodies using E. coli mutator cells
38. Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity
39. The fibronectin type III domain as a scaffold for novel binding proteins
40. Cotranslational folding of globin
41. Solution properties of E. coli expressed VH domain of anti-neuraminidase antibody NC41
42. Folding of an enzyme into an active conformation while bound as a peptidyl-tRNA to the ribosome
43. Mimicking somatic hypermutation: Affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain
44. Cloning and expression of human V-genes derived from phage display libraries as fully assembled human anti-TNF alpha monoclonal antibodies
45. Enzymatic activity of the ribosome-bound nascent polypeptide
46. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
47. An in vitro polysome display system for identifying ligands from very large peptide libraries
48. Phage antibodies: Filamentous phage displaying antibody variable domains
49. Model systems to study the parameters determining the success of phage antibody selections on complex antigens
50. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains
51. Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies
52. In vitro virus: Bonding of mRNA bearing puromycin at the 3′ terminal end to the C-terminal end of its encoded protein on the ribosome in vitro
53. Disrupting the hydrophobic patches at the antibody variable/constant domain interface - Improved in vivo folding and physical characterisation of an engineered scFv fragment
54. Design and expression of soluble CTLA-4 variable domain as a scaffold for the display of functional polypeptides
55. Antibodies against HIV-1 from phage display libraries: Mapping of an immune response and progress towards antiviral immunotherapy
56. Targeted therapy of cancer with recombinant immunotoxins
57. Improvements in the immunoprecipitation of specific mRNA. Isolation of highly purified conalbumin mRNA in high yield
58. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1
59. Uncoupling translocation from translation: Implication for transport of proteins across membranes
60. Antibodies from Escherichia coli
61. New protein engineering approaches to multivalent and bispecific antibody fragments
62. Error-prone retrotransposition: Rime of the ancient mutators
63. Antibody scFvs fragments without disulphide bonds made by molecular evolution
64. The mutant distribution of an RNA species replicated by Q beta replicase
65. An antibody single-domain phage display library of a native heavy chain variable region: Isolation of functional single-domain VH molecules with a unique interface
66. Identification of a human anti-CD55 single-chain Fv by subtractive panning of a phage library using tumor and nontumor cell lines
67. RNA peptide fusions for the in vitro selection of peptides and proteins
68. Totally in vitro protein selection using mRNA-protein fusions and ribosome display
69. Structural analysis of the nurse shark (new) antigen receptor (NAR): Molecular convergence of NAR and unusual mammalian immunoglobulins
70. Ribosome display: An in vitro method for selection and evolution of antibodies from libraries
71. Engineered protein scaffolds for molecular recognition
72. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface
73. The RNA-dependent RNA polymerases of different members of the family Flaviviridae exhibit similar properties in vitro
74. Structural correlates of an anticarcinoma antibody: Identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only
75. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase
76. CTLA-4 a negative regulator of T-lymphocyte activation
77. Making antibodies by phage display technology
78. Molecular evolution by staggered extension process (StEP) in vitro recombination